Myelodysplastic syndromes, version 2.2015 featured updates to the NCCN guidelines

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 13, Issue 3, 2015, Pages 261-272

  Greenberg, Peter L ^a   Stone, Richard M ^b   Bejar, Rafael ^c   Bennett, John M ^d   Bloomfield, Clara D ^e   Borate, Uma ^f   De Castro, Carlos M ^g   Deeg, H Joachim ^h   DeZern, Amy E ⁱ   Fathi, Amir T ^j   Frankfurt, Olga ^k   Gaensler, Karin ^l   Garcia Manero, Guillermo ^m   Griffiths, Elizabeth A ⁿ   Head, David ^o   Klimek, Virginia ^p   Komrokji, Rami ^q   Kujawski, Lisa A ^r   Maness, Lori J ^s   O'Donnell, Margaret R ^t   Pollyea, Daniel A ^u   Scott, Bart ^h   Shami, Paul J ^v   Stein, Brady L ^k   Westervelt, Peter ^w   Wheeler, Benton ^x   Shead, Dorothy A ^y   Smith, Courtney ^y   more..

^a STANFORD CANCER INSTITUTE   (United States)

^b DANA FARBER BRIGHAM AND WOMEN S CANCER CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^e OHIO STATE UNIVERSITY   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g DUKE CANCER INSTITUTE   (United States)

^h SEATTLE CANCER CARE ALLIANCE   (United States)

ⁱ JOHNS HOPKINS UNIVERSITY   (United States)

^j MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^k NORTHWESTERN UNIVERSITY   (United States)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁿ ROSWELL PARK CANCER INSTITUTE   (United States)

^o VANDERBILT INGRAM CANCER CENTER   (United States)

^p MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^q H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^r UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^s UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^t CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^u University of Colorado Cancer Center   (United States)

^v UNIVERSITY OF UTAH   (United States)

^w BARNES JEWISH HOSPITAL   (United States)

^x UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^y National Comprehensive Cancer Network   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL EVALUATION; COST EFFECTIVENESS ANALYSIS; GENE MUTATION; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM REVISED; MEDICAL DECISION MAKING; MYELODYSPLASTIC SYNDROME; PATIENT CARE; PRACTICE GUIDELINE; PROFESSIONAL PRACTICE; PROGNOSTIC ASSESSMENT; REVIEW; COST BENEFIT ANALYSIS; DISEASE MANAGEMENT; GENETIC SCREENING; GENETICS; MYELODYSPLASTIC SYNDROMES; PROGNOSIS;

COST-BENEFIT ANALYSIS; DISEASE MANAGEMENT; GENETIC TESTING; HUMANS; MYELODYSPLASTIC SYNDROMES; PROGNOSIS;

EID: 84924366934     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2015.0038     Document Type: Review

References (58)

1. Greenberg PL, Stone RM, Bejar R, et al. NCCN Clinical Practice Guidelines in Oncology: Myelodysplastic Syndromes, Version 2.2015. Available at: NCCN.org. Accessed February 6, 2015
2. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079- 2088. Erratum in Blood 1998;2091:1100
3. Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007;25:3503-3510
4. Greenberg PL, Tuechler H, Schanz J, et al. Revised International Prognostic Scoring System (IPSS-R) for myelodysplastic syndromes. Blood 2012;120:2454-2465
5. Wang H, Wang XQ, Xu XP, Lin GW. Cytogenetic evolution correlates with poor prognosis in myelodysplastic syndrome. Cancer Genet Cytogenet 2010;196:159-166
6. de Souza Fernandez T, Ornellas MH, Otero de Carvalho L, et al. Chromosomal alterations associated with evolution from myelodysplastic syndrome to acute myeloid leukemia. Leuk Res 2000;24:839-848
7. Schanz J, Tuchler H, Sole F, et al. New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol 2012;30:820-829
8. Greenberg PL, Cosler LE, Ferro SA, Lyman GH. The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines. J Natl Compr Canc Netw 2008;6:942-953
9. Mishra A, Corrales-Yepez M, Ali NA, et al. Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes. Am J Hematol 2013;88:566-570
10. Neukirchen J, Lauseker M, Blum S, et al. Validation of the revised international prognostic scoring system (IPSS-R) in patients with myelodysplastic syndrome: A multicenter study. Leuk Res 2014;38:57-64
11. Della Porta MG, Alessandrino EP, Bacigalupo A, et al. Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R. Blood 2014;123:2333-2342
12. Alessandrino EP, Della Porta MG, Bacigalupo A, et al. WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: A study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood 2008;112:895-902
13. Ades L, Lamarque M, Raynaud S, et al. Revised-IPSS (IPSS-R) is a powerful tool to evaluate the outcome of mds patient treated with azacitidine (AZA): the Groupe Francophone Des Myelodysplasies (GFM) experience [abstract]. Blood 2012;120:Abstract 422
14. Cermak J, Mikulenkova D, Brezinova J, Michalova K. A reclassification of myelodysplastic syndrome (MDS) patients of RAEB-1 subgroup according to IPSS-R improves discrimination of high risk patients and better predicts overall survival. A retrospective analysis of 49 patients [abstract]. Blood 2012;120:Abstract 4957
15. Messa E, Gioia D, Evangelista A, et al. High predictive value of the revised International Prognostic Scoring System (IPSS-R): An external analysis of 646 patients from a multiregional Italian MDS registry [abstract]. Blood 2012;120:Abstract 1702
16. Voso MT, Fenu S, Latagliata R, et al. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database. J Clin Oncol 2013;31:2671-2677
17. Valcarcel D, Sanz G, Ortega M, et al. Identification of poor risk patients in low and intermediate-1 (Int-1) IPSS MDS with the new IPSS-R index and comparison with other prognostic indexes. A study by the Spanish Group of MDS (GESMD) [abstract]. Blood 2012;120:Abstract 702
18. Warlick ED, Hirsch BA, Nguyen PL, et al. Comparison of IPSS and IPSS-R scoring in a population based myelodysplastic syndromes (MDS) study [abstract]. Blood 2012;120:Abstract 3841
19. Malcovati L, Hellstrom-Lindberg E, Bowen D, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood 2013;122:2943-2964
20. Kroger N. Allogeneic stem cell transplantation for elderly patients with myelodysplastic syndrome. Blood 2012;119:5632-5639
21. della Porta MG, Alessandrino EP, Jackson CH, et al. Decision analysis of allogeneic stem cell transplantation in patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System (IPSS-R) [abstract]. Blood 2014;124:Abstract 531
22. Ok CY, Hasserjian RP, Fox PS, et al. Application of the international prognostic scoring system-revised in therapy-related myelodysplastic syndromes and oligoblastic acute myeloid leukemia. Leukemia 2014;28:185-189
23. Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011;364:2496-2506
24. Bejar R, Stevenson KE, Caughey BA, et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol 2012;30:3376-3382
25. Papaemmanuil E, Gerstung M, Malcovati L, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 2013;122:3616-3627
26. Haferlach T, Nagata Y, Grossmann V, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia 2014;28:241-247
27. Itzykson R, Kosmider O, Renneville A, et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol 2013;31:2428-2436
28. Patnaik MM, Itzykson R, Lasho TL, et al. ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: A two-center study of 466 patients. Leukemia 2014;28:2206-2212
29. Walter MJ, Ding L, Shen D, et al. Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia 2011;25:1153-1158
30. Graubert TA, Shen D, Ding L, et al. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet 2012;44:53-57
31. Thol F, Kade S, Schlarmann C, et al. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood 2012;119:3578-3584
32. Makishima H, Yoshida K, Nguyen N, et al. Somatic SETBP1 mutations in myeloid malignancies. Nat Genet 2013;45:942-946
33. Patnaik MM, Lasho TL, Hodnefield JM, et al. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood 2012;119:569-572
34. Bejar R, Papaemmanuil E, Haferlach T, et al. TP53 mutation status divides MDS patients with complex karyotypes into distinct prognostic risk groups: Analysis of combined datasets from the International Working Group for MDS-Molecular Prognosis Committee [abstract]. Blood 2014;124:Abstract 532
35. Sebaa A, Ades L, Baran-Marzack F, et al. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion. Genes Chromosomes Cancer 2012;51:1086-1092
36. Jadersten M, Saft L, Smith A, et al. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol 2011;29:1971-1979
37. Mallo M, Del Rey M, Ibanez M, et al. Response to lenalidomide in myelodysplastic syndromes with del(5q): influence of cytogenetics and mutations. Br J Haematol 2013;162:74-86
38. Jadersten M, Saft L, Pellagatti A, et al. Clonal heterogeneity in the 5qsyndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression. Haematologica 2009;94:1762-1766
39. Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med 2014;371:2488-2498
40. Hicks LK, Bering H, Carson KR, et al. The ASH Choosing Wisely campaign: five hematologic tests and treatments to question. Blood 2013;122:3879-3883
41. Napolitano LM, Kurek S, Luchette FA, et al. Clinical practice guideline: red blood cell transfusion in adult trauma and critical care. J Trauma 2009;67:1439-1442
42. Carson JL, Grossman BJ, Kleinman S, et al. Red blood cell transfusion: A clinical practice guideline from the AABB. Ann Intern Med 2012;157:49-58
43. Retter A, Wyncoll D, Pearse R, et al. Guidelines on the management of anaemia and red cell transfusion in adult critically ill patients. Br J Haematol 2013;160:445-464
44. Patton J, Reeves T, Wallace J. Effectiveness of darbepoetin alfa versus epoetin alfa in patients with chemotherapy-induced anemia treated in clinical practice. Oncologist 2004;9:451-458
45. Patton JF, Sullivan T, Mun Y, et al. A retrospective cohort study to assess the impact of therapeutic substitution of darbepoetin alfa for epoetin alfa in anemic patients with myelodysplastic syndrome. J Support Oncol 2005;3:419-426
46. List AF. Emerging data on IMiDs in the treatment of myelodysplastic syndromes (MDS). Semin Oncol 2005;32:S31-35
47. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006;355:1456-1465
48. Revicki DA, Brandenburg NA, Muus P, et al. Health-related quality of life outcomes of lenalidomide in transfusion-dependent patients with lowor intermediate-1-risk myelodysplastic syndromes with a chromosome 5q deletion: results from a randomized clinical trial. Leuk Res 2013;37:259-265
49. Oliva EN, Latagliata R, Lagana C, et al. Lenalidomide in International Prognostic Scoring System low and intermediate-1 risk myelodysplastic syndromes with del(5q): An Italian phase II trial of health-related quality of life, safety and efficacy. Leuk Lymphoma 2013;54:2458-2465
50. Giagounidis A, Mufti GJ, Mittelman M, et al. Outcomes in RBC transfusiondependent patients with low-/intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: A subset analysis from the MDS-004 study. Eur J Haematol 2014;93:429-438
51. Goss TF, Szende A, Schaefer C, et al. Cost effectiveness of lenalidomide in the treatment of transfusion-dependent myelodysplastic syndromes in the United States. Cancer Control 2006;13(Suppl):17-25
52. Exjade [prescribing information]. Stein, Switzerland: Novartis Pharma Stein AG; 2013. Available at: Http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/021882s019lbl.pdf. Accessed January 23, 2015
53. Tolley K, Oliver N, Miranda E, et al. Cost effectiveness of deferasirox compared to desferrioxamine in the treatment of iron overload in lowerrisk, transfusion-dependent myelodysplastic syndrome patients. J Med Econ 2010;13:559-570
54. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study. Lancet Oncol 2009;10:223-232
55. Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006;24:3895-3903
56. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the Cancer and Leukemia Group B. J Clin Oncol 2002;20:2429-2440
57. Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007;109:52-57
58. Kogan AJ, Dunn JD. Myelodysplastic syndromes: Health care management considerations. Manag Care 2009;18:25-28; discussion 28-29.